Heart & blood pressure · Mobile, AL
Heart and blood pressure studies in Mobile, AL
11 recruiting studies have a site in Mobile.
11 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Merck Sharp & Dohme LLC
- Location
- Mobile, AL + 23 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
AstraZeneca
- Location
- Mobile, AL + 151 other US sites
- Eligibility basics
- Ages 40+
- Recruiting
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
CVRx, Inc.
- Location
- Mobile, AL + 16 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Boehringer Ingelheim
- Location
- Mobile, AL + 91 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Mobile, AL + 136 other US sites
- Eligibility basics
- Ages 45–99
- Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
Boston Scientific Corporation
- Location
- Mobile, AL + 39 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
AstraZeneca
- Location
- Mobile, AL + 206 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Amgen
- Location
- Mobile, AL + 193 other US sites
- Eligibility basics
- Ages 50–105
- RecruitingPhase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
- Location
- Mobile, AL + 47 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Anthos Therapeutics, Inc.
- Location
- Mobile, AL + 131 other US sites
- Eligibility basics
- Ages 65+
- RecruitingPhase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
DalCor Pharmaceuticals
- Location
- Mobile, AL + 112 other US sites
- Eligibility basics
- Ages 45+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.